5 Best Multi-Bagger Stocks to Buy Now

3. Lantheus Holdings, Inc. (NASDAQ:LNTH)

12-Month Returns as of August 2: 186.13%

Lantheus Holdings, Inc. (NASDAQ:LNTH) is a global diagnostics and research company headquartered in Massachusetts. It manufactures products to assist medical practitioners in the diagnosis and treatment of heart, cancer, and several other diseases. On May 9, B. Riley analyst Justin Walsh initiated Lantheus Holdings, Inc. (NASDAQ:LNTH)’s coverage with a Buy rating and a price target of $91. Walsh calls  the company a “leading diagnostic imaging and nuclear medicine company”. Moreover, he expects FY2022 results to be doubled compared to the last year, owing to its prostate cancer imaging agent Pylarify’s launch.

Investment portfolios showed a fairly positive sentiment towards Lantheus Holdings, Inc. (NASDAQ:LNTH) in the first quarter of 2022. According to the Insider Monkey database, 35 hedge funds were bullish on the company with a combined stake value of $523.52 million. In the previous quarter, Lantheus Holdings, Inc. (NASDAQ:LNTH) was a part of 15 hedge fund portfolios.

Here is what Clearbridge Investments had to say about Lantheus Holdings, Inc. (NASDAQ:LNTH) in its Q1 2022 investor letter:

“While companies with immature business models and no profits exist throughout the market, there are certain sectors where they congregate more easily, such as health care. As access to cheap capital recedes, however, many of these specialty drug and biotech companies will likely find it challenging to dismiss long periods of unprofitability. While we have had limited exposure in the sector, our focus on finding high-quality companies at attractive valuations has yielded positive results. For example, Lantheus Holdings (NASDAQ:LNTH) is a global leader in medical diagnostic imaging whose core business suffered during the COVID-19 pandemic due to a dramatic decline in hospital visits. As hospitals return to a level of normalcy, Lantheus’s core business has rebounded. Additionally, in late 2021 the company received approval for its new radio-pharmacological drug, Pylarify, for the treatment of prostate cancer, and initial sales have been well ahead of expectations. We believe it has a strong future in oncology diagnosis and treatment. As a result, Lantheus was our strongest individual performer for the first quarter.”